Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T19:03:44.298Z.
Calculation as of: 2026-10-06T19:03:44.298Z.
Quote observation: 2026-10-06T18:59:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b7fd3b5d8e417d78924f6cd313032c2aac5600bd184120b35a4860f29c1b1599
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Tiziana Life Sciences Ltd
Market Cap
$69.04M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$69.19M
Free Cash Flow Yield
28.30%
TTM Avg
14.79%
3Y Avg
25.02%
5Y Avg
20.90%
Market Cap
$68.71M
Free Cash Flow Yield
183.14%
TTM Avg
137.42%
3Y Avg
137.42%
5Y Avg
137.42%
Market Cap
$68.08M
Free Cash Flow Yield
N/A
TTM Avg
6.20%
3Y Avg
5.62%
5Y Avg
4.88%
Market Cap
$71.89M
Free Cash Flow Yield
N/A
TTM Avg
0.09%
3Y Avg
0.09%
5Y Avg
0.09%
Market Cap
$72.09M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$65.85M
Free Cash Flow Yield
N/A
TTM Avg
24.06%
3Y Avg
24.06%
5Y Avg
24.06%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tiziana Life Sciences Ltd (TLSA) | $69.04M | N/A | N/A | N/A | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $69.19M | 28.30% | 14.79% | 25.02% | 20.90% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.71M | 183.14% | 137.42% | 137.42% | 137.42% |
| Champions Oncology, Inc. (CSBR)vs › | $68.08M | N/A | 6.20% | 5.62% | 4.88% |
| Cingulate Inc. (CING)vs › | $67.01M | N/A | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $66.82M | N/A | N/A | N/A | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $71.89M | N/A | 0.09% | 0.09% | 0.09% |
| Gain Therapeutics, Inc. (GANX)vs › | $72.09M | N/A | N/A | N/A | N/A |
| XBiotech Inc. (XBIT)vs › | $65.85M | N/A | 24.06% | 24.06% | 24.06% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.84M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
